[AsCNP] Symposium
AsCNP » [AsCNP] Symposium
Sun. Oct 13, 2019 10:30 AM - 12:10 PM Room 14 (Palace Room A)
Organizer / Chair: Kohji FUKUNAGA (Department of Pharmacology, Tohoku University Graduate School of Pharmaceutical Sciences, Japan), Co-chair: Masatoshi TAKEDA (Osaka Kawasaki Rehabilitation University, Japan), Discussants: Yasushi YABUKI (Department of Pharmacology, Tohoku University Graduate School of Pharmaceutical Sciences, Japan), Ichiro KAWAHATA (Department of Pharmacology, Tohoku University Graduate School of Pharmaceutical Sciences, Japan)
Novel therapeutic strategies are rapidly developing in the Asian countries including Japan and Taiwan. Dr Rita P-Y Chen is young reader in Taiwan Neuroscience Society and discovered intranasal delivered peptide as Alzheimer disease (AD) therapeutics. Dr Kohji Fukunaga also introduce novel disease-modifying therapeutics for Lewy body disease. Moreover, to clinical investigation for those novel therapeutics, the physician should recruit early MCI patients to prevent the disease progression. In this context, Dr Manabu Ikeda will give us the genetic background information for AD and DLB diagnosis. And Dr Yang form Taiwan introduce super sensitive immunoassay technology for AD and DLB. Taken together, in this symposium, we provide not only attractive candidate for AD and DLB therapy, but also new information of biomarker for neurodegenerative disease diagnosis. We also invite young investigators as discussants who are working on AD and DLB research. We take more time to discuss deeply in the biomarker and therapeutics with young investigators in the symposium.
10:30 AM - 10:35 AM
○Kohji FUKUNAGA (Department of Pharmacology, Tohoku University Graduate School of Pharmaceutical Sciences, Japan)
Schedule
Like
10:35 AM - 11:00 AM
○Rita PY CHEN1, 2 (1. Institute of Biological Chemistry, Academia Sinica, Taiwan, 2. Institute of Biochemical Sciences, National Taiwan University, Taiwan)
Schedule
Like
11:00 AM - 11:25 AM
○Kohji FUKUNAGA (Department of Pharmacology, Tohoku University Graduate School of Pharmaceutical Sciences, Japan)
Schedule
Like
11:25 AM - 11:50 AM
○Takashi MORIHARA1, Kenichi NAGATA1, Luc PAILLARD2, Satoshi OBIKA3, Yuya KASAHARA4, Michael SILVERMAN6, Hiroyasu AKATSU5, Yoshio HASHIZUME5, Manabu IKEDA7 (1. Dept of Precision Medicine for Dementia, Osaka University Graduate School of Medicine, Japan, 2. Université de Rennes 1, France, 3. Graduate School of Pharmaceutical Sciences, Osaka University, Japan, 4. Center for Drug Design Research, National Institute of Biomedical Innovation, Japan, 5. Choju Medical Institute, Fukushimura Hospital, Japan, 6. Simon Fraser University, Canada, 7. Dept of Psychiatry, Osaka University Graduate School of Medicine, Japan)
Schedule
Like
11:50 AM - 12:10 PM
○Shieh-Yueh YANG1, Ming-Jang CHIU2, Chin-Hsien LIN2, Wei-Che LIN3, Fu-Chi YANG4, Pai-Yi CHIU5, W.P. CHEN6, H.C. LIU1 (1MagQu Co., Ltd., Xindian District, New Taiwan City, Taiwan, 2Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan, 3Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, Kaohsiung, Taiwan, 4Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, 5Department of Neurology, Show Chwan Memorial Hospital, Changhua City, Changhua County, Taiwan)
Schedule
Like